Thymus Cancer Pipeline Review, H2 2012


#146083

79pages

Global Markets Direct

$ 2000

In Stock


Thymus Cancer Pipeline Review, H2 2012

Global Markets Directs, 'Thymus Cancer Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Thymus Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thymus Cancer. Thymus Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Thymus Cancer.
  • A review of the Thymus Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Thymus Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Thymus Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thymus Cancer Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Thymus Cancer 9
Thymus Cancer Therapeutics under Development by Companies 11
Thymus Cancer Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Thymus Cancer Therapeutics Products under Development by Companies 16
Thymus Cancer Therapeutics Products under Investigation by Universities/Institutes 17
Companies Involved in Thymus Cancer Therapeutics Development 18
ZIOPHARM Oncology, Inc. 18
TopoTarget A/S 19
Nerviano Medical Sciences S.r.l. 20
Thymus Cancer Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Cisplatin + Adriamycin + Cyclophosphamide - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 28
imatinib - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
belinostat - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
milciclib - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cisplatin + Etoposide + Radiation Therapy - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Carboplatin + Paclitaxel - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Belinostat + Cisplatin + Doxorubicin + Cyclophosphamide - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Docetaxel + Cisplatin - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
cisplatin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Octreotide + Prednisone - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Alvocidib + Depsipeptide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
saracatinib - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Docetaxol + Cisplatin + Radiation Therapy - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Cetuximab + Cisplatin + Doxorubicin + Cyclophosphamide - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Carboplatin + Paclitaxel - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
K562-GM Vaccine + Cyclophosphamide + Celecoxib - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Cisplatin + Vincristine + Doxorubicin + Etoposide - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
cixutumumab - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
premetrexed - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
sunitinib malate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Allogeneic Tumor Cell Vaccine + Iscomatrix + Celecoxib + Cyclophosphamide - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Anti-Thymocyte Globulin + Busulfan + Cyclophosphamide + Cyclosporine + Melphalan + Methylprednisolone + Umbilical Cord Blood Transplantation + Radiation Therapy - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 62
cisplatin - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
cixutumumab - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Capecitabine + Gemcitabine - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
palifosfamide + etoposide + carboplatin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Gemcitabine + Nedaplatin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
AZD6244 + MK-2206 + Lapatinib + Erlotinib + Sunitinib - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Paclitaxel + Carboplatin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Thymus Cancer Therapeutics Drug Profile Updates 74
Thymus Cancer Therapeutics Discontinued Products 76
Thymus Cancer Therapeutics - Dormant Products 77

Appendix 78
Methodology 78
Coverage 78
Secondary Research 78
Primary Research 78
Expert Panel Validation 78
Contact Us 79
Disclaimer 79

Number of Products Under Development for Thymus Cancer, H2 2012 9
Products under Development for Thymus Cancer Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Products under Development by Companies, H2 2012 16
Products under Investigation by Universities/Institutes, H2 2012 17
ZIOPHARM Oncology, Inc., H2 2012 18
TopoTarget A/S, H2 2012 19
Nerviano Medical Sciences S.r.l., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Thymus Cancer Therapeutics Drug Profile Updates 74
Thymus Cancer Therapeutics Discontinued Products 76
Thymus Cancer Therapeutics Dormant Products 77
Number of Products under Development for Thymus Cancer, H2 2012 9
Products under Development for Thymus Cancer Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26